EUROPEAN JOURNAL OF HAEMATOLOGY

Scope & Guideline

Transforming Hematology Through Rigorous Research

Introduction

Delve into the academic richness of EUROPEAN JOURNAL OF HAEMATOLOGY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0902-4441
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 2024
AbbreviationEUR J HAEMATOL / Eur. J. Haematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The European Journal of Haematology focuses on advancing the field of hematology through high-quality research that encompasses various aspects of blood disorders, treatment modalities, and patient outcomes. The journal serves as a platform for disseminating significant findings related to hematological malignancies and related conditions, emphasizing clinical, laboratory, and translational research.
  1. Hematological Malignancies:
    The journal covers a wide range of hematological malignancies, including acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma, focusing on innovative treatment strategies, clinical outcomes, and prognostic factors.
  2. Transplantation and Cellular Therapies:
    Research related to hematopoietic stem cell transplantation, including conditioning regimens, graft-versus-host disease, and CAR-T cell therapies, is a core area of interest, highlighting advancements and challenges in these fields.
  3. Clinical Trials and Real-World Evidence:
    The journal emphasizes the importance of clinical trials and real-world studies, exploring the efficacy and safety of new therapies, treatment patterns, and patient-reported outcomes in hematological diseases.
  4. Genetic and Molecular Insights:
    Studies investigating the genetic and molecular underpinnings of hematological disorders are featured, contributing to the understanding of disease mechanisms and the development of targeted therapies.
  5. Quality of Life and Patient-Centered Care:
    Research addressing health-related quality of life, psychosocial aspects of treatment, and patient-centered approaches in hematology is also a significant focus, reflecting the holistic view of patient care.
The European Journal of Haematology has identified several emerging themes and trends in recent publications, reflecting the dynamic nature of research in the field. These themes indicate a shift towards more innovative and personalized approaches in the diagnosis and treatment of hematological disorders.
  1. Immunotherapy and Targeted Treatments:
    There is a notable increase in research related to immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, highlighting their efficacy and safety in treating various hematological malignancies.
  2. Real-World Evidence and Comparative Effectiveness:
    Emerging studies focus on real-world evidence and comparative effectiveness research, assessing treatment outcomes in diverse patient populations and informing clinical decision-making.
  3. Genomic and Biomarker Studies:
    Research investigating genomic alterations and biomarkers for prognostication and treatment response is on the rise, reflecting a trend towards personalized medicine in hematology.
  4. Quality of Life and Supportive Care Interventions:
    An increasing emphasis on quality of life assessments, psychosocial interventions, and supportive care strategies for patients with hematological disorders indicates a broader focus on holistic patient care.
  5. COVID-19 Impact on Hematology Patients:
    The impact of COVID-19 on patients with hematological conditions has become a significant area of research, exploring infection rates, treatment adaptations, and outcomes in this vulnerable population.

Declining or Waning

While the journal continuously adapts to the evolving landscape of hematological research, certain themes have shown a decline in frequency or relevance in recent publications. This waning interest may reflect shifts in research priorities or advancements in other areas.
  1. Traditional Chemotherapy Approaches:
    Research focusing on traditional chemotherapy regimens for hematological malignancies appears to be declining, as newer, more targeted therapies and immunotherapies gain prominence in clinical practice.
  2. Basic Laboratory Techniques:
    Papers centered on basic laboratory techniques in hematology, such as routine blood tests and traditional cytogenetic analyses, have decreased as the field moves toward more advanced molecular diagnostics and personalized medicine.
  3. Epidemiological Studies without Novel Insights:
    Epidemiological studies that do not provide novel insights or advancements in understanding disease burden or treatment outcomes are becoming less frequent, as the focus shifts to studies with actionable results.

Similar Journals

Clinical Lymphoma Myeloma & Leukemia

Exploring Innovations in Blood Cancer Treatment
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

LEUKEMIA & LYMPHOMA

Transforming the landscape of cancer treatment and care.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

HAEMATOLOGICA

Transforming Hematology Through Knowledge and Integrity
Publisher: FERRATA STORTI FOUNDATIONISSN: 0390-6078Frequency: 12 issues/year

HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.

Hematologie

Empowering the Future of Hematological Sciences
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

LEUKEMIA

Advancing the Frontiers of Hematology and Oncology
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

ACTA HAEMATOLOGICA

Elevating Research in Hematology and Beyond
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Turkish Journal of Hematology

Unveiling the latest breakthroughs in blood health and treatment.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

LEUKEMIA RESEARCH

Catalyzing discoveries in the fight against leukemia.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

ANNALS OF HEMATOLOGY

Exploring breakthroughs in blood disorders and treatments.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Blood and Lymphatic Cancer-Targets and Therapy

Bridging Research and Practice in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.